{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T05:57:18Z","timestamp":1790575038105,"version":"4.1.0"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Identifying immune features that distinguish asymptomatic autoantibody-positive at-risk individuals from patients with established autoimmune disease is key to understanding the evolution from autoreactivity to established autoimmune disease. This study investigated immune characteristics of anti-SSA\u2013positive at-risk individuals, including pregnant women, compared with patients with Sj\u00f6gren\u2019s disease (SjD) and healthy donors (HDs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Peripheral blood samples were obtained from asymptomatic anti-SSA\u2013positive women (at-risk individuals; n = 7, including two ongoing pregnancies with congenital heart block [CHB] and one woman with a prior CHB pregnancy), patients with SjD (n = 10), and age- and sex-matched HDs (n = 21; median age 35.1 years; 100% female). T- and B-cell subsets and IFN signaling molecules, including STAT1, phosphorylated STAT1 (pSTAT1), STAT2, IRF1, and IRF9, were analyzed by flow cytometry. In addition, circulating IFN subtypes were quantified in available plasma samples using the NULISA platform.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At-risk individuals showed lower ANA and rheumatoid factor titers and lacked anti-SSB autoantibodies compared with patients with SjD. At-risk individuals had B-cell distributions similar to HDs, whereas patients with SjD showed a typical increase in na\u00efve B cells and reduced pre-switched and switched memory B-cell frequencies, together with increased CD8+ T-cell frequencies and a non-significant trend toward reduced double-negative T-cell frequencies. At-risk individuals also showed significantly increased IFN activity, reflected by Siglec-1 (CD169) expression on CD14+ monocytes, compared with HDs, while levels tended to be lower than in patients with SjD. Two of three women with a current or previous CHB pregnancy had the highest Siglec-1 levels within the at-risk group. Cytokine profiling revealed a stage-associated IFN pattern, with IFN-\u03b11 and IFN-\u03c9 already increased in at-risk individuals, whereas IFN-\u03b3, IFN-\u03b21, and type III IFNs showed a trend toward higher levels in established SjD. Intracellular STAT1 expression was elevated across CD19+ B-cell subsets in at-risk individuals compared with HDs, but was generally less pronounced than in SjD. IRF9 was also increased in B-cell subsets from at-risk individuals and patients with SjD compared with HDs. Similar findings were observed in CD3+ T-cell subsets, where STAT1 and IRF9 expression were elevated in at-risk individuals compared with HDs and were largely comparable to levels observed in patients with SjD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our data suggest that increased type I IFN activity and IFN-associated signaling in T- and B-cell subsets are already present in anti-SSA\u2013positive at-risk individuals. In contrast, altered B- and T-cell homeostasis was restricted to established SjD, indicating progression from autoreactivity toward overt autoimmune disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1723672","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T05:45:06Z","timestamp":1790574306000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Immune profiling of anti-SSA\u2013positive at-risk individuals reveals increased type I IFN activity preceding lymphocyte abnormalities in Sj\u00f6gren\u2019s disease"],"prefix":"10.3389","volume":"17","author":[{"given":"Jacob","family":"Ritter","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin","place":["Berlin, Germany"]},{"name":"German Rheumatism Research Center (Deutsches Rheuma-Foschungszentrum (DRFZ)), a Leibniz Institute","place":["Berlin, Germany"]},{"name":"Berlin Institute of Health at Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Berlin Institute of Health (BIH) Academy","place":["Berlin, Germany"]},{"name":"Department of Endocrinology and Metabolic Diseases, Charit\u00e9-Universit\u00e4tsmedizin Berlin, corporate Member of Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu Berlin","place":["Berlin, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana-Luisa","family":"Stefanski","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin","place":["Berlin, Germany"]},{"name":"German Rheumatism Research Center (Deutsches Rheuma-Foschungszentrum (DRFZ)), a Leibniz Institute","place":["Berlin, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arman","family":"Aue","sequence":"additional","affiliation":[{"name":"German Rheumatism Research Center (Deutsches Rheuma-Foschungszentrum (DRFZ)), a Leibniz Institute","place":["Berlin, Germany"]},{"name":"Department of Nephrology and Intensive Care, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin","place":["Berlin, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hector","family":"Rincon-Arevalo","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin","place":["Berlin, Germany"]},{"name":"German Rheumatism Research Center (Deutsches Rheuma-Foschungszentrum (DRFZ)), a Leibniz Institute","place":["Berlin, Germany"]},{"name":"Department of Nephrology and Intensive Care, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin","place":["Berlin, Germany"]},{"name":"Grupo de Inmunolog\u00eda Celular e Inmunogen\u00e9tica, Facultad de Medicina, Instituto de Investigaciones M\u00e9dicas, Universidad de Antioquia (UdeA)","place":["Medell\u00edn, Colombia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Rapino","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin","place":["Berlin, Germany"]},{"name":"German Rheumatism Research Center (Deutsches Rheuma-Foschungszentrum (DRFZ)), a Leibniz Institute","place":["Berlin, Germany"]},{"name":"Reumatologia, Dipartimento di Scienze Cliniche Internistiche, Anestesiologiche Cardiovascolari, Sapienza University","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali Necmi","family":"Eren","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin","place":["Berlin, Germany"]},{"name":"German Rheumatism Research Center (Deutsches Rheuma-Foschungszentrum (DRFZ)), a Leibniz Institute","place":["Berlin, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yidan","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin","place":["Berlin, Germany"]},{"name":"German Rheumatism Research Center (Deutsches Rheuma-Foschungszentrum (DRFZ)), a Leibniz Institute","place":["Berlin, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduard","family":"Nitschke","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin","place":["Berlin, Germany"]},{"name":"German Rheumatism Research Center (Deutsches Rheuma-Foschungszentrum (DRFZ)), a Leibniz Institute","place":["Berlin, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Van Duc","family":"Dang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin","place":["Berlin, Germany"]},{"name":"German Rheumatism Research Center (Deutsches Rheuma-Foschungszentrum (DRFZ)), a Leibniz Institute","place":["Berlin, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika","family":"Wiedemann","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin","place":["Berlin, Germany"]},{"name":"German Rheumatism Research Center (Deutsches Rheuma-Foschungszentrum (DRFZ)), a Leibniz Institute","place":["Berlin, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Schrezenmeier","sequence":"additional","affiliation":[{"name":"German Rheumatism Research Center (Deutsches Rheuma-Foschungszentrum (DRFZ)), a Leibniz Institute","place":["Berlin, Germany"]},{"name":"Berlin Institute of Health at Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Berlin Institute of Health (BIH) Academy","place":["Berlin, Germany"]},{"name":"Department of Nephrology and Intensive Care, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin","place":["Berlin, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreia C.","family":"Lino","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin","place":["Berlin, Germany"]},{"name":"German Rheumatism Research Center (Deutsches Rheuma-Foschungszentrum (DRFZ)), a Leibniz Institute","place":["Berlin, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Szelinski","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin","place":["Berlin, Germany"]},{"name":"German Rheumatism Research Center (Deutsches Rheuma-Foschungszentrum (DRFZ)), a Leibniz Institute","place":["Berlin, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"D\u00f6rner","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin","place":["Berlin, Germany"]},{"name":"German Rheumatism Research Center (Deutsches Rheuma-Foschungszentrum (DRFZ)), a Leibniz Institute","place":["Berlin, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa021933","article-title":"Development of autoantibodies before the clinical onset of systemic lupus erythematosus","volume":"349","author":"Arbuckle","year":"2003","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20018","article-title":"Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors","volume":"50","author":"Nielen","year":"2004","journal-title":"Arthritis Rheum"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/art.39214","article-title":"Prediction of sj\u00f6gren's syndrome years before diagnosis and identification of patients with early onset and severe disease course by autoantibody profiling","volume":"67","author":"Theander","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/s0031-3025(16)38413-6","article-title":"Range of antinuclear antibodies in \"healthy\" individuals","volume":"40","author":"Tan","year":"1997","journal-title":"Arthritis Rheum"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/bf02205560","article-title":"Anti-Ro (SSA)\/La (SSB) antibodies and sj\u00f6gren's syndrome","volume":"9","author":"Moutsopoulos","year":"1990","journal-title":"Clin Rheumatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1093\/cei\/uxae073","article-title":"Prevalence and clinical significance of anti-SSA antibody in the Chinese health screening population","volume":"218","author":"Jia","year":"2024","journal-title":"Clin Exp Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-225349","article-title":"Blood RNA-sequencing across the continuum of ANA-positive autoimmunity reveals insights into initiating immunopathology","volume":"83","author":"Carter","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213386","article-title":"Prediction of autoimmune connective tissue disease in an at-risk cohort: prognostic value of a novel two-score system for interferon status","volume":"77","author":"Md Yusof","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.210703","article-title":"Health outcomes of 215 mothers of children with autoimmune congenital heart block: analysis of the French Neonatal Lupus Syndrome Registry","volume":"49","author":"Miniaoui","year":"2022","journal-title":"J Rheumatol"},{"key":"B10","first-page":"95","article-title":"Autoimmune congenital heart block and primary sj\u00f6gren's syndrome: characterisation and outcomes of 49 cases","author":"Brito-Zer\u00f3n","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210927","article-title":"High maternal expression of SIGLEC1 on monocytes as a surrogate marker of a type I interferon signature is a risk factor for the development of autoimmune congenital heart block","volume":"76","author":"Lisney","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2024.103243","article-title":"Elevated unphosphorylated STAT1 and IRF9 in T and B cells of primary sj\u00f6gren's syndrome: novel biomarkers for disease activity and subsets","volume":"147","author":"Ritter","year":"2024","journal-title":"J Autoimmun"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/sji.12662","article-title":"Transcription profiling of peripheral B cells in antibody-positive primary sj\u00f6gren's syndrome reveals upregulated expression of CX3CR1 and a type I and type II interferon signature","volume":"87","author":"Imgenberg-Kreuz","year":"2018","journal-title":"Scand J Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3138\/ctr.145.3","article-title":"Diminished peripheral blood memory B cells and accumulation of memory B cells in the salivary glands of patients with sj\u00f6gren's syndrome","volume":"46","author":"Hansen","year":"2002","journal-title":"Arthritis Rheumatism"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2018.1","article-title":"B cells in the pathogenesis of primary sj\u00f6gren syndrome","volume":"14","author":"Nocturne","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221604","article-title":"Proteogenomic analysis of the autoreactive B cell repertoire in blood and tissues of patients with sj\u00f6gren's syndrome","author":"Broeren","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-225069","article-title":"CD8(+) tissue-resident memory T cells are expanded in primary sj\u00f6gren's disease and can be therapeutically targeted by CD103 blockade","volume":"83","author":"Mauro","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2010.05.005","article-title":"What do we know about memory B cells in primary sj\u00f6gren\u2019s syndrome","volume":"9","author":"Hansen","year":"2010","journal-title":"Autoimmun Rev"},{"key":"B19","doi-asserted-by":"publisher","first-page":"8299","DOI":"10.1038\/s41467-025-63935-9","article-title":"Comparative single-cell and spatial profiling of anti-SSA-positive and anti-centromere-positive sj\u00f6gren's disease reveals common and distinct immune activation and fibroblast-mediated inflammation","volume":"16","author":"Inamo","year":"2025","journal-title":"Nat Commun"},{"key":"B20","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1002\/art.39859","article-title":"2016 American College of Rheumatology\/European League Against Rheumatism classification criteria for primary sj\u00f6gren's syndrome: a consensus and data-driven methodology involving three international patient cohorts","volume":"76","author":"Shiboski","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.110619","article-title":"EULAR sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary sjogren's syndrome","volume":"69","author":"Seror","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2016-000292","article-title":"SIGLEC1 is a biomarker of disease activity and indicates extraglandular manifestation in primary sj\u00f6gren's syndrome","volume":"2","author":"Rose","year":"2016","journal-title":"RMD Open"},{"key":"B23","doi-asserted-by":"publisher","first-page":"7238","DOI":"10.1038\/s41467-023-42834-x","article-title":"NULISA: a proteomic liquid biopsy platform with attomolar sensitivity and high multiplexing","volume":"14","author":"Feng","year":"2023","journal-title":"Nat Commun"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/art.20276","article-title":"Abnormalities in peripheral B cell memory of patients with primary sj\u00f6gren's syndrome","volume":"50","author":"Hansen","year":"2004","journal-title":"Arthritis Rheum"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/nri1604","article-title":"Mechanisms of type-I- and type-II-interferon-mediated signalling","volume":"5","author":"Platanias","year":"2005","journal-title":"Nat Rev Immunol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.immuni.2019.07.007","article-title":"Differential activation of the transcription factor IRF1 underlies the distinct immune responses elicited by type I and type III interferons","volume":"51","author":"Forero","year":"2019","journal-title":"Immunity"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-000989","article-title":"Type I IFN system activation in newborns exposed to Ro\/SSA and La\/SSB autoantibodies in utero","volume":"6","author":"Hedlund","year":"2020","journal-title":"RMD Open"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa695","article-title":"Increased expression of interleukin-21-inducible genes in minor salivary glands are associated with primary sj\u00f6gren's syndrome disease characteristics","author":"Chen","year":"2020","journal-title":"Rheumatol (Oxford)"},{"key":"B29","doi-asserted-by":"crossref","DOI":"10.1002\/art.41558","article-title":"Interleukin-7\/interferon axis drives T cell and salivary gland epithelial cell interactions in sj\u00f6gren's syndrome","volume":"73","author":"Rivi\u00e8re","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.681941","article-title":"The transcriptome of paired major and minor salivary gland tissue in patients with primary sj\u00f6gren's syndrome","volume":"12","author":"Verstappen","year":"2021","journal-title":"Front Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01135","article-title":"A positive feedback amplifier circuit that regulates interferon (IFN)-stimulated gene expression and controls type I and type II IFN responses","volume":"9","author":"Michalska","year":"2018","journal-title":"Front Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00029","article-title":"Canonical and non-canonical aspects of JAK-STAT signaling: lessons from interferons for cytokine responses","volume":"8","author":"Majoros","year":"2017","journal-title":"Front Immunol"},{"key":"B33","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1189\/jlb.0412210","article-title":"Induction of BAFF expression by IFN-\u03b3 via JAK\/STAT signaling pathways in human intestinal epithelial cells","volume":"93","author":"Woo","year":"2013","journal-title":"J Leukoc Biol"},{"key":"B34","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.1501061","article-title":"The expression of BAFF is controlled by IRF transcription factors","volume":"196","author":"Sj\u00f6strand","year":"2016","journal-title":"J Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1186\/ar1912","article-title":"B cell-activating factor of the tumor necrosis factor family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in primary sj\u00f6gren\u2019s syndrome","volume":"8","author":"Ittah","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"B36","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1136\/annrheumdis-2019-216786","article-title":"Natural killer cells and type II interferon in Ro\/SSA and La\/SSB autoantibody-exposed newborns at risk of congenital heart block","volume":"80","author":"Ivanchenko","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208140","article-title":"Altered type II interferon precedes autoantibody accrual and elevated type I interferon activity prior to systemic lupus erythematosus classification","volume":"75","author":"Munroe","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ard.2025.01.042","article-title":"Predictors of arthritis development in individuals at risk of rheumatoid arthritis: a 5-year follow-up study from a large cohort","volume":"84","author":"Frazzei","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"B39","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s12884-016-0927-7","article-title":"Characterization of B cells in healthy pregnant women from late pregnancy to post-partum: a prospective observational study","volume":"16","author":"Lima","year":"2016","journal-title":"BMC Pregnancy Childbirth"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2011-200708","article-title":"Impaired type I and III interferon response to rhinovirus infection during pregnancy and asthma","volume":"67","author":"Forbes","year":"2012","journal-title":"Thorax"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis377","article-title":"Pregnant women have attenuated innate interferon responses to 2009 pandemic influenza A virus subtype H1N1","volume":"206","author":"Forbes","year":"2012","journal-title":"J Infect Dis"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1723672\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T05:45:07Z","timestamp":1790574307000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1723672\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":41,"alternative-id":["10.3389\/fimmu.2026.1723672"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1723672","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,28]]},"article-number":"1723672"}}